Barry Hyman Terms Quotations

I think, ... that Pfizer is going to benefit from their merger with Warner-Lambert. I think that makes a very good deal. But most pharmaceutical companies do eventually strike deals with biotech companies in terms of marketing their product. And the genomic companies don't have a lot of cash. They have a lot of high valuations, but they don't have a lot of dollars to spend. So, they usually look toward the pharmaceutical sector to help them out, which usually helps both sectors.

We don't have a predominance of negative news, day-to-day, in terms of economic events.

This story is a little bit surprising in terms of the players, not in terms of the deal.

The intermediate background look in terms of interest rates peaking and the economy slowing to a more sustainable pace without any undue harm is slowly going to play itself out. I would be very shocked if the GDP came in anywhere higher than estimates because Wall Street is already expressing its confidence that the economy is slowing down.

They're (investors) looking for the Fed to be absolutely aggressive and see the economy as slow as can be and to be measured in terms of understanding how important the consumer is at this point. And how important the stock market is to consumer confidence.

I don't think there's anything that will deter the Fed from lowering interest rates in August. I think the story is going to be the continuing belief that there is a mixed story on Wall Street that has been brought out, in terms of technology. The visibility story is changing somewhat to the 'we see the bottom in sight' scenario.